DuPont de Nemours, Inc. (NYSE: DD) today announced the launch of two new slurried chromatography resins, the AmberChrom XT20 SL and XT30 SL, as part of its bioprocessing portfolio. The resins are slurried versions of the existing AmberChrom XT line and are designed to eliminate the resin‑hydration step required before column packing, thereby reducing capital investment and streamlining downstream purification of oligonucleotide and peptide therapeutics.
The new resins target manufacturers of oligonucleotide and peptide drugs, a rapidly growing class of targeted medicines used to treat genetic disorders, metabolic conditions, and certain cancers. By allowing direct packing from delivery to column, the XT20 SL and XT30 SL resins cut preparation time, lower equipment needs, and maintain the high resolution required for complex separations. This operational advantage is expected to improve throughput and reduce costs for biopharmaceutical producers.
The launch expands DuPont’s presence in the life‑sciences market, complementing its existing AmberChrom CG and TQ1 resins. The company highlighted that the new products will support the increasing demand for efficient, scalable purification solutions in the growing oligonucleotide and peptide therapeutic space, positioning DuPont to capture a larger share of the bioprocessing market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.